ibusinesslines.com
ibusinesslines.com December 19, 2017


FDA Approves Ogivri, Biosimilar to Herceptin, to Treat HER2

05 December 2017, 02:18 | Melissa Porter

Mylan and Biocon are among a host of biosim developers that are working to grab a piece of Roche’s global cancer fortunes

Mylan and Biocon are among a host of biosim developers that are working to grab a piece of Roche’s global cancer fortunes

Mylan N.V. (MYL) and Biocon Ltd. said that the U.S. Food and Drug Administration has approved Mylan's Ogivri or trastuzumab-dkst, a biosimilar to Herceptin or trastuzumab, co-developed with Biocon.

"It will allow us to bring this important biosimilar - the first of its kind - to market in the USA, expanding cancer-patient access to more affordable treatment".

The agency's commissioner, Scott Gottlieb, said that biosimilar approvals help "to promote competition that can lower health care costs".

The biosimilar's approval was based on a review of evidence including extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data, and other clinical safety and effectiveness data. "We're committed to taking new policy steps to advance our biosimilar pathway and promote more competition for biological drugs".


Shares of Biocon hit a one-year high in Monday's trade as the markets cheered after the USFDA validated its biosimilar cancer drug Trastuzumab and approved it for the USA market on Friday night.

But Ogivri also shares Herceptin's side effects, which can include heart disease (cardiomyopathy), infusion reactions, and lung damage, and it may also harm a developing fetus.

Mylan and Biocon's biosimilar for Herceptin also is under review by regulatory authorities in Australia, Canada, Europe and several additional markets. It will allow us to bring this important biosimilar, expanding cancer-patient access to more affordable treatment.

"We are extremely pleased with the acceptance of our [marketing authorization application in Europe]", Rajiv Malik, Mylan's president, said in a press release. Ogivri is one of many biosimilars in our robust pipeline that we look forward to introducing in the coming years as part of our ongoing commitment to increasing access to important medicines for patients.



Other News

Trending Now

Venezuelan President Announces Oil-Backed Cryptocurrency "Petro" to Combat 'US Blockade'
Maduro says he is trying to combat a Washington-backed conspiracy to sabotage his government and end socialism in Latin America. The commodity-backed cryptocurrency, the petro, is unlikely to bring them any immediate relief.

California Legislature To Investigate Sexual Misconduct Allegations Against Woodland Hills Lawmaker
The Times had been preparing a report on her accusations against Dababneh, and sought the assemblyman's comment late last week. In previous weeks, Lopez had recounted what happened to her to several news outlets but did not name her alleged attacker.

US Defence Secretary Mattis arrives in Pakistan
Qamar Javed Bajwa, separately, during his day-long visit, the second tour of a high profile USA official in less than a month. Asked if Mattis set any timelines, the official said the urgency of the matter was communicated.

Why Spain Vs. Portugal Is 'Can't-Miss' Game Of Group Stage
Ajax and Morocco star Hakim Ziyech has given his reaction to the draw for the World Cup group stages which took place on Friday. The Germans will then face Sweden and South Korea in Group F.

EA is making much-needed improvements to Star Wars Battlefront II
Iden Versio's campaign will continue on December 13th in the Resurrection chapter which charts the rise of The First Order. Finally, players will have the ability to earn triple the previous daily limit of credits in Arcade Mode, totaling 1,500.

Altered Carbon: Netflix Dystopian Drama Gets Start Date
The show is reportedly Netflix's most expensive series to date and this new trailer definitely has my attention. Consciousness can be digitized, human bodies are interchangeable and death is no longer permanent ...

Bill O'Reilly Sued For Defamation By Fox Employee He Allegedly Abused
O'Reilly would make other comments including to The Hollywood Reporter , which is cited in today's lawsuit. She went to HR and other organization administrators to gripe about him a few times .